Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab + pomalidomide + dexamethasone versus standard of care in previously treated multiple myeloma
2025-524028-23-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Cevostamab + pomalidomide + dexamethasone with Standard of care (2 arms). Primary endpoints: MRD-negative complete response rate at 9 months and Progression-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-524028-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524028-23-00.